Effects of drug strategies under the guidance of genetic testing on 1-year clinical outcome of hospitalized patients with schizophrenia

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000030320

Enrollment

Unknown

Registered

2020-02-28

Start date

2020-03-01

Completion date

Unknown

Last updated

2020-03-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Schizophrenia

Interventions

Experimental Group:Adjust the dosage according to the results of genetic testing

Control Group:Adjust the dose according to experience

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Aged >=18 and < 65 years of patients with schizophrenia; 2. Course < 2 years; 3. Accord with ICD - 10 diagnostic criteria for schizophrenia; 4. Always has not taken the risperidone and olanzapine; 5. Further improve the treatment effect of patients and reduce the side effects of drugs.

Exclusion criteria

Exclusion criteria: 1. Substance abuse or dependence patients; 2. Treatment-resistant schizophrenia patients; 3. Craniocerebral trauma history and lead to coma patients; 4. With serious and unstable body disease; 5. Patients with mental retardation; 6. Patients treated with MECT or clozapine in the past 3 months.

Design outcomes

Primary

Measure	Time frame
PANSS;CGI;TESS;GAF;	—

Countries

China

Contacts

Public ContactYing Yang

Shandong Mental Health Center

1817602498@qq.com+86 18705317353

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026